Activity of linezolid against anaerobic bacteria

Behra-Miellet, Josette; Calvet, L.; Dubreuil, L.

doi:10.1016/s0924-8579(03)00087-6

Cited by 48 publications

(21 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study has also reported 100% susceptibility in 265 clinical anaerobic isolates [20]. Susceptibility cut off for linezolid has not been described by CLSI, previous surveys have used a cut off of 4 ug/mL as susceptible and 8 ug/mL as resistant [20].…”

Section: Discussionmentioning

confidence: 99%

“…Susceptibility cut off for linezolid has not been described by CLSI, previous surveys have used a cut off of 4 ug/mL as susceptible and 8 ug/mL as resistant [20]. Linezolid has been reported to be very potent drug against all strains of Fusobacteria, Prevotella and Porphyromonas and is also reported to provide microbiological clearance as well as clinical improvement in anaerobic sepsis due to multidrug resistant B. fragilis infection [20,21].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High rate of non-susceptibility to metronidazole and clindamycin in anaerobic isolates: Data from a clinical laboratory from Karachi, Pakistan

et al. 2015

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

High rate of non-susceptibility to metronidazole and clindamycin in anaerobic isolates: Data from a clinical laboratory from Karachi, Pakistan

et al. 2015

View full text Add to dashboard Cite

“…Thus, a fluoroquinolone might not be a suitable substitute for carbapenems. Behra-Miellet et al reported that linezolid is likely to be active against most anaerobes (5). It may be a potential candidate for antimicrobial therapy if resistance to carbapenems develops.…”

Section: Discussionmentioning

confidence: 99%

Increasing Trends in Antimicrobial Resistance among Clinically Important Anaerobes and Bacteroides fragilis Isolates Causing Nosocomial Infections: Emerging Resistance to Carbapenems

Liu¹,

Huang

Liao

et al. 2008

Antimicrob Agents Chemother

145

View full text Add to dashboard Cite

This study reports data on the susceptibilities to five commonly used antianaerobic agents of five clinically frequently encountered anaerobes from 2000 to 2007 and to Bacteroides fragilis isolates causing nosocomial infections from 1990 to 2006. There was a trend of decreasing susceptibilities of these anaerobes to ampicillinsulbactam, cefmetazole, chloramphenicol, and clindamycin with time during the study period. The rates of susceptibility to clindamycin and cefmetazole for all clinical isolates of Bacteroides fragilis isolates were higher than those of isolates associated with nosocomial infections. The MICs of 207 anaerobic blood isolates collected in 2006 to 14 antimicrobial agents were determined by the agar dilution method. The rates of nonsusceptibility to imipenem and meropenem were 7% and 12% for B. fragilis isolates (n ‫؍‬ 60), 7% and 3% for Bacteroides thetaiotamicron isolates (n ‫؍‬ 30), 4% and 4% for Fusobacterium species (n ‫؍‬ 27), 6% and 0% for Prevotella species (n ‫؍‬ 16), 15% and 0% for Clostridium species (n ‫؍‬ 28), and 0% and 0% for Peptostreptococcus species (n ‫؍‬ 32). The rates of susceptibility to moxifloxacin were 90% for B. fragilis isolates, 87% for B. thetaiotaomicron isolates, 81% for Fusobacterium species, 75% for Prevotella species, 93% for Clostridium species, and 78% for Peptostreptococcus species. Thirty-six percent of Clostridium species and 12% of Peptostreptococcus species were not susceptible to metronidazole. Comparison of the data with the data from a previous survey from the same institute in 2002 revealed higher rates of nonsusceptibility to carbapenems, especially for B. fragilis, Fusobacterium species, and Prevotella species isolates. The high rates of nonsusceptibility to commonly used antianaerobic agents mandate our attention, and periodic monitoring of the trend of the resistance is crucial.

show abstract

“…and Staphylococcus spp., including vancomycinresistant enterococci, meticillin-resistant Staphylococcus aureus (MRSA) and meticillin-resistant CoNS [6][7][8][9]. Linezolid is also active against anaerobes, atypical microbes such as Chlamydia and Mycoplasma spp., some rapidly growing mycobacteria, and selected Gram-negative bacilli [10][11][12]. Linezolid, or N-([S]-[3-[3-fluoro-4-morpholinophenyl]-2-oxo-5-oxazolidinyl] methyl) acetamide, is a totally synthetic antimicrobial agent structurally unrelated to other agents, with unique mechanism of action [6,7].…”

Section: Introductionmentioning

confidence: 99%

Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review

Kocher¹,

Müller²,

Resch³

2010

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Linezolid is an antibiotic of the oxazolidinone class that has bacteriostatic and bactericidal activity against a broad range of Gram-positive bacteria, including multiresistant pathogens. Owing to increasing resistance of Gram-positive pathogens to traditional antibiotics such as vancomycin, the oxazolidinones were introduced into therapy. The aim of this review was to summarise actual data on the pharmacokinetics, safety and clinical use of linezolid in preterm infants. The Medline and EMBASE databases were searched using the term 'linezolid' combined with 'newborn', 'neonate', 'preterm' and 'premature' for papers published between January 1987 and June 2009. Studies reporting on a population including preterm infants and other age groups as well as case reports on preterm infants only were acceptable for analysis. Five studies and eight case reports were identified evaluating linezolid in preterm infants. A dosage regimen of 10mg/kg body weight given either orally or intravenously every 8h in infants aged >or=1 week and the same dose given every 12h in infants <1 week was shown to be safe and effective with a mean treatment duration of 10-28 days. In summary, linezolid was shown to be a safe and effective alternative to vancomycin in the treatment of infections with multiresistant Gram-positive pathogens in preterm infants.

show abstract

Activity of linezolid against anaerobic bacteria

Cited by 48 publications

References 12 publications

High rate of non-susceptibility to metronidazole and clindamycin in anaerobic isolates: Data from a clinical laboratory from Karachi, Pakistan

High rate of non-susceptibility to metronidazole and clindamycin in anaerobic isolates: Data from a clinical laboratory from Karachi, Pakistan

Increasing Trends in Antimicrobial Resistance among Clinically Important Anaerobes and Bacteroides fragilis Isolates Causing Nosocomial Infections: Emerging Resistance to Carbapenems

Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review

Contact Info

Product

Resources

About